MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2800
-0.0700 (-5.19%)
As of 2:51PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.3500
Open1.3700
Bid1.2600 x 1000
Ask1.2700 x 1100
Day's Range1.2600 - 1.4100
52 Week Range1.0300 - 3.3400
Volume88,239
Avg. Volume123,867
Market Cap34.694M
Beta (3Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.5740
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced its financial results for the third quarter ended September 30, 2018. Additionally, the Company announced potential upcoming milestones and recent corporate developments. Walter Klemp, Chairman and CEO of Moleculin, said, “We maintain a sharp focus on the continuing development of our broad-based oncology portfolio and in effectively advancing those solutions through the FDA regulatory process.

  • GlobeNewswire6 days ago

    Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that a new mechanism of action may have been uncovered expanding the potential use of its inhibitor of glycolysis, WP1122.

  • GlobeNewswire13 days ago

    Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, with initial results showing bioavailability of the drug in patients. Walter Klemp, Moleculin’s Chairman and CEO added, “We believe WP1066 is a first-in-class compound capable of stimulating a natural immune response in animal models while directly attacking tumors by modulating transcriptional activity and repressing what we call ‘oncogenic transcription factors.’  Chief among these is STAT3, considered a master regulator of tumor progression.  While activity in animal models has been very promising, one of the goals of this trial was to determine the potential for bioavailability in humans.  The initial positive indications of this clinical trial increase our confidence that WP1066 has the potential to become an important drug in the treatment of certain cancers.

  • GlobeNewswire20 days ago

    Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that investigators at Emory University will present animal model data supporting the potential of WP1066 to treat pediatric brain tumors at the upcoming Society for Neuro-Oncology Annual Scientific Meeting.

  • GlobeNewswirelast month

    Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors

    Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that new data relating to its molecule WP1122 will be presented at the upcoming Society for Neuro-Oncology Annual Scientific Meeting. Walter Klemp, Moleculin’s Chairman and CEO added, “Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus.

  • GlobeNewswire2 months ago

    Moleculin’s Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson

    In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (MBRX) has initiated a Phase 1 clinical trial of a new first-in-class cancer drug candidate, a small molecule compound discovered by Prof. Waldemar Priebe at  The University of Texas MD Anderson Cancer Center and known as WP1066. The compound has been shown in animal models to both inhibit an important cell signaling protein STAT3 that is involved in cell growth and proliferation and considered critical to tumor development, while also stimulating an immune response.  The first glioblastoma patient has received the initial doses of WP1066, which were apparently well tolerated, in the physician-sponsored IND (investigational new drug) study at MD Anderson Cancer Center.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Winnebago Industries, Inc. (NYSE: WGO ) stock was ...

  • ACCESSWIRE6 months ago

    Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar

    Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...

  • Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?
    Simply Wall St.6 months ago

    Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)?

    Today, I will be analyzing Moleculin Biotech Inc’s (NASDAQ:MBRX) recent ownership structure, an important but not-so-popular subject among individual investors. The impact of a company’s ownership structure affects both itsRead More...

  • Marketwired7 months ago

    Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference

    Moleculin Biotech, Inc., , a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System......

  • ACCESSWIRE7 months ago

    Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients

    Stock Monitor: Moleculin Biotech Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI ...